(44), who showed that STAT3 promotes drug persistence in CML by shifting cellular metabolism toward glycolysis, thereby supporting leukemic stem cell survival. This evidence concerns the gene STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.